A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B

David B. Duggan; Maria Teresa Santarelli; Kenneth Zamkoff; Stuart Lichtman; John Ellerton; Robert Cooper; Bernard Poiesz; James R. Anderson; Clara D. Bloomfield; Bruce A. Peterson; Arlan J. Gottlieb

doi:10.1097/00002371-199208000-00006

A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B

David B. Duggan, Maria Teresa Santarelli, Kenneth Zamkoff, Stuart Lichtman, John Ellerton, Robert Cooper, Bernard Poiesz, James R. Anderson, Clara D. Bloomfield, Bruce A. Peterson, Arlan J. Gottlieb

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Interleukin-2 (IL-2) and interferon-β (IFN-β) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-β is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-β in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-β is not effective therapy for NHL in the doses and schedule used in this study.

Original language	English (US)
Pages (from-to)	115-122
Number of pages	8
Journal	Journal of Immunotherapy
Volume	12
Issue number	2
DOIs	https://doi.org/10.1097/00002371-199208000-00006
State	Published - Aug 1992

Keywords

Interferon-β
Interleukin- 2
Lymphokine-activated killer cells
Natural killer cells
Non-Hodgkin' s lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/00002371-199208000-00006

Find It

Find It at U of M Libraries

Cite this

Duggan, D. B., Santarelli, M. T., Zamkoff, K., Lichtman, S., Ellerton, J., Cooper, R., Poiesz, B., Anderson, J. R., Bloomfield, C. D., Peterson, B. A., & Gottlieb, A. J. (1992). A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B. Journal of Immunotherapy, 12(2), 115-122. https://doi.org/10.1097/00002371-199208000-00006

Duggan, DB, Santarelli, MT, Zamkoff, K, Lichtman, S, Ellerton, J, Cooper, R, Poiesz, B, Anderson, JR, Bloomfield, CD, Peterson, BA & Gottlieb, AJ 1992, 'A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B', Journal of Immunotherapy, vol. 12, no. 2, pp. 115-122. https://doi.org/10.1097/00002371-199208000-00006

@article{05c785028090433c994287c3ff81f646,

title = "A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B",

abstract = "Interleukin-2 (IL-2) and interferon-β (IFN-β) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-β is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-β in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-β is not effective therapy for NHL in the doses and schedule used in this study.",

keywords = "Interferon-β, Interleukin- 2, Lymphokine-activated killer cells, Natural killer cells, Non-Hodgkin' s lymphoma",

author = "Duggan, {David B.} and Santarelli, {Maria Teresa} and Kenneth Zamkoff and Stuart Lichtman and John Ellerton and Robert Cooper and Bernard Poiesz and Anderson, {James R.} and Bloomfield, {Clara D.} and Peterson, {Bruce A.} and Gottlieb, {Arlan J.}",

year = "1992",

month = aug,

doi = "10.1097/00002371-199208000-00006",

language = "English (US)",

volume = "12",

pages = "115--122",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B

AU - Duggan, David B.

AU - Santarelli, Maria Teresa

AU - Zamkoff, Kenneth

AU - Lichtman, Stuart

AU - Ellerton, John

AU - Cooper, Robert

AU - Poiesz, Bernard

AU - Anderson, James R.

AU - Bloomfield, Clara D.

AU - Peterson, Bruce A.

AU - Gottlieb, Arlan J.

PY - 1992/8

Y1 - 1992/8

N2 - Interleukin-2 (IL-2) and interferon-β (IFN-β) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-β is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-β in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-β is not effective therapy for NHL in the doses and schedule used in this study.

AB - Interleukin-2 (IL-2) and interferon-β (IFN-β) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-β is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-β in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-β is not effective therapy for NHL in the doses and schedule used in this study.

KW - Interferon-β

KW - Interleukin- 2

KW - Lymphokine-activated killer cells

KW - Natural killer cells

KW - Non-Hodgkin' s lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0026778389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026778389&partnerID=8YFLogxK

U2 - 10.1097/00002371-199208000-00006

DO - 10.1097/00002371-199208000-00006

M3 - Article

C2 - 1504052

AN - SCOPUS:0026778389

SN - 1524-9557

VL - 12

SP - 115

EP - 122

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

IS - 2

ER -

A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B

Abstract

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this